TORONTO, Jan. 31, 2013 /CNW/ - Amorfix Life Sciences Ltd. announced
today that Mr. Warren Whitehead has joined the Company as Chief
Financial Officer effective February 1, 2013. Janet Clennett will
continue on as part of the management team and will assume the position
of Director of Finance.
Mr. Whitehead has been in the pharmaceutical industry for more than 25
years and has previously held top management positions in a number of
leading private and publicly owned pharmaceutical companies. Prior to
joining Amorfix, Mr. Whitehead was CFO at Arius Research Inc., where he
provided financial guidance and leadership during the acquisition of
ARIUS by Roche in 2008 and prior to that he was CFO at Labopharm, Inc.
where he completed a series of public equity financings and a NASDAQ
IPO. He is currently a member of the Board of Directors of PlantForm
Corporation and of Lorus Therapeutics.
"We are pleased to have such an experienced financial executive join the
senior management at Amorfix", said Dr. Robert Gundel, Amorfix
President and Chief Executive Officer. "Mr. Whitehead's financial
expertise and his vast experience in both the biotechnology industry
and the financial sector will provide the necessary leadership to
advance our products through to commercialization, while maximizing
returns to our shareholders".
Dr. Neil Cashman, Amorfix founder and Chairman of the Board said, "On
behalf of the Board of Directors, I would like to thank Janet Clennett
for all of her hard work and dedication to Amorfix over the past few
years and we are pleased that Ms. Clennett will remain as a valuable
member of the Amorfix management team in her new role. We welcome Mr.
Whitehead to the Company and look forward to working with him as part
of the management team."
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product
development company developing therapeutic antibodies and diagnostics
targeting misfolded protein diseases. Amorfix utilizes its
computational discovery platform, ProMIS™, to predict novel Disease
Specific Epitopes (DSEs) on the molecular surface of misfolded
proteins. Using this technology, Amorfix is developing novel antibody
therapeutics and companion diagnostics for cancer and amyotrophic
lateral sclerosis (ALS). In addition, Amorfix has developed two
proprietary technologies to specifically identify very low levels of
misfolded proteins in a biological sample: Epitope Protection™ and
AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these
technologies has generated a cerebrospinal fluid (CSF) screening test
for both Alzheimer's disease (AD) and mild cognitive impairment (MCI),
and an ultrasensitive method for detecting the hallmark of AD,
aggregated beta-Amyloid, in brain tissue, CSF and blood from animal
models of AD. For more information about Amorfix, visit www.amorfix.com.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release. This information release may
contain certain forward-looking information. Such information involves
known and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially different
from those implied by statements herein, and therefore these statements
should not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current beliefs
as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by the Company in its
public securities filings, actual events may differ materially from
current expectations. The Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise, unless required by law.
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life
SOURCE: Amorfix Life Sciences Ltd.
For further information:
Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899